Organization | Hospital Pablo Tobón Uribe

Hospital Pablo Tobón Uribe Report issue

Academic/Hospital Phase 1 Phase 3 Phase 4

Founded: Medellín Colombia

Organization Overview

First Clinical Trial

2011

NCT01118403

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2020

Timeline

NOW

Now

Alternative names

Hospital Pablo Tobin Uribe | Hospital Pablo Tobon Uribe | Hospital Pablo Tobón Uribe

Active Ingredients

Drugs in Phase 4 Trials (2)

procaine benzylpenicillin (novocaine) (1 trial)

sulbactam (unasyn) (1 trial)

Drugs in Phase 3 Trials (1)

COVID-19 convalescent plasma (1 trial)

Drugs in Phase 1 Trials (2)

hydroxyurea (hydrea) (1 trial)

pegylated carboxyhemoglobin (1 trial)

Drugs in Other Trials (4)

insulin human (humulin) (1 trial)

levobupivacaine (chirocaine) (1 trial)

midazolam (versed) (1 trial)

oxygen (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Anemia, Sickle Cell (Phase 1)

Pneumonia (Phase 4)

Pneumonia, Ventilator-Associated (Phase 4)

Overview

Highest Phase: Phase 4
# of Trials: 4
# of Trial APIs: 9